Trials in Philadelphia, Pennsylvania
Here are the top 10 medical studies for lung cancer in Philadelphia, Pennsylvania
Popular Filters
Phase 3 Trials
Small Molecule Kinase Inhibitor
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
Monoclonal Antibodies
Serplulimab + Chemotherapy for Small Cell Lung Cancer
Recruiting3 awardsPhase 3
Florham Park, New Jersey
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
PARP Inhibitor
Ceralasertib + Durvalumab for Lung Cancer
Recruiting3 awardsPhase 3
Allentown, Pennsylvania
This trial tests a new combination of drugs (ceralasertib and durvalumab) against a standard treatment (docetaxel) in patients with advanced lung cancer who didn't respond to previous treatments. The new combination aims to weaken cancer cells and boost the immune system, while the standard treatment directly kills the cancer cells.
Monoclonal Antibodies
Ramucirumab + Pembrolizumab vs Chemotherapy for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Newark, Delaware
This trial compares ramucirumab+pembrolizumab vs chemo for non-small cell lung cancer. Ramucirumab+pembrolizumab may stop tumors from growing and spreading, while chemo kills/stops cells from dividing/spreading. Results may help find out if this combo is more effective than chemo.
Trials With No Placebo
Small Molecule Kinase Inhibitor
Lazertinib + Amivantamab for Non-Small Cell Lung Cancer
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial is testing a new, easier to use formulation of amivantamab, which has the potential to reduce administration time and improve the patient and physician experience.
Small Molecule Inhibitor
RMC-6236 for Cancer
Recruiting1 awardPhase 1
New York, New York
This trial is testing a new drug called RMC-6236, which is taken by mouth and targets a protein called RAS. It is aimed at adults with advanced cancers that have specific mutations in the RAS protein. The drug works by blocking this protein, which helps stop the cancer cells from growing.
Kinase Inhibitor
Avutometinib + Adagrasib for Lung Cancer
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing a combination of two drugs, avutometinib (VS-6766) and adagrasib, in patients with a specific type of lung cancer who have not responded to previous treatments. The drugs aim to stop the cancer cells from growing by blocking the signals that tell them to multiply. Adagrasib, a KRASG12C inhibitor, irreversibly and selectively binds KRASG12C, locking it in its inactive state.
SHP2 Inhibitor
BBP-398 + Nivolumab for Lung Cancer
Recruiting1 awardPhase 1
Philadelphia, Pennsylvania
This trial tests BBP-398 and nivolumab in patients with advanced lung cancer who have a specific genetic mutation and haven't responded to other treatments. BBP-398 blocks a protein that helps cancer grow, while nivolumab boosts the immune system to fight the cancer.
Monoclonal Antibodies
Tarlatamab Combo for Small Cell Lung Cancer
Recruiting1 awardPhase 1
Newark, Delaware
This trial is testing a new drug called tarlatamab combined with treatments that help the immune system fight cancer, and sometimes with chemotherapy. It targets cancer patients who need new treatment options. Tarlatamab attacks cancer cells directly, while other treatments boost the immune response or kill cancer cells.
Monoclonal Antibodies
IOV-4001 for Melanoma and Lung Cancer
Recruiting1 awardPhase 1 & 2
New York, New York
This trial is testing IOV-4001, a modified immune cell treatment, in adults with advanced melanoma or lung cancer. The treatment aims to improve the ability of the patient's own immune cells to attack cancer by disabling a gene that helps cancer hide.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.